ArticleChemMedChem2026
Design, Synthesis, and Evaluation of Coumarin-Rasagiline Hybrids as Multifunctional Neuroprotective Agents.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The design of hybrid molecules with multifunctional profiles has emerged as a promising strategy in medicinal chemistry, particularly for tackling complex disorders such as neurodegenerative diseases. There is an urgent need for therapeutic agents capable of acting on multiple pathological targets to both control neuronal death and support the recovery of already compromised neuronal populations. In this study, we synthesized and evaluated a series of hybrid compounds combining a coumarin scaffold with an alkynylamine moiety inspired by rasagiline. These molecules were studied for their potential as human monoamine oxidase (hMAO) inhibitors, antioxidants, and neuroprotective agents. Five compounds demonstrated inhibitory activity against hMAO-B in the micromolar range, along with significant neuroprotective effects against oxidative stress induced by Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.